Autolus Therapeutics plc Files 8-K on Shareholder Matters
Ticker: AUTL · Form: 8-K · Filed: 2025-06-27T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: AUTL
TL;DR
Autolus filed an 8-K on shareholder votes. All good.
AI Summary
Autolus Therapeutics plc filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders as of June 26, 2025. The filing details the company's corporate structure and operational information, including its principal executive offices in London, United Kingdom.
Why It Matters
This filing provides an update on corporate governance and shareholder decisions for Autolus Therapeutics, which is crucial for investors to understand the company's direction and management.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information about significant financial events or operational changes that would inherently increase risk.
Key Players & Entities
- Autolus Therapeutics plc (company) — Registrant
- June 26, 2025 (date) — Date of earliest event reported
- June 27, 2025 (date) — Date of Report
- London (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on matters submitted to a vote of security holders as of June 26, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Autolus Therapeutics plc.
In which jurisdiction was Autolus Therapeutics plc incorporated or organized?
Autolus Therapeutics plc was incorporated or organized in England and Wales.
What is the address of the registrant's principal executive offices?
The address of the registrant's principal executive offices is The Mediaworks, 191 Wood Lane, London, W12 7FP, United Kingdom.
What is the telephone number of the registrant, including area code?
The registrant's telephone number, including area code, is (44) 20 3829 6230.
From the Filing
0001730463-25-000046.txt : 20250627 0001730463-25-000046.hdr.sgml : 20250627 20250627084710 ACCESSION NUMBER: 0001730463-25-000046 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250626 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250627 DATE AS OF CHANGE: 20250627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 251082462 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 autl-20250626.htm 8-K autl-20250626 0001730463 FALSE 0001730463 2025-06-26 2025-06-26 0001730463 sic:Z8880 2025-06-26 2025-06-26 0001730463 us-gaap:CommonClassAMember 2025-06-26 2025-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) (44) 20 3829 6230 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share* * The Nasdaq Stock Market LLC * * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Ite